Education
About Us
Working with TipRanks
Follow Us
CSPC Pharmaceutical Group (HK:1093)
:1093
RESEARCH TOOLSreports
1093 Stock Chart & Stats
Day’s Range― - ―
52-Week RangeHK$4.27 - HK$7.83
Previous CloseN/A
Volume61.16M
Average Volume (3M)129.09M
Market Cap
HK$63.73B
Enterprise ValueN/A
Total Cash (Recent Filing)¥937.28M
Total Debt (Recent Filing)¥1.30B
Price to Earnings (P/E)13.8
Beta0.98
Next Earnings
May 21, 2025EPS Estimate
0.17Next Dividend Ex-Date
Jun 04, 2025Dividend Yield6.83%
Share Statistics
EPS (TTM)0.40
Shares Outstanding11,543,702,000
10 Day Avg. Volume172,781,984
30 Day Avg. Volume129,088,332
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)2.85
Price to Cash Flow (P/CF)N/A
P/FCF Ratio0.00
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
HK$5.44Price Target Upside-1.59% Downside
Rating ConsensusModerate Buy
Number of Analyst Covering4
---
CSPC Pharmaceutical Group News
PremiumCompany Announcements
CSPC Pharmaceutical Group Reports 2024 Earnings Decline
PremiumCompany Announcements
CSPC Pharmaceutical Group Declares Final Dividend for 2024
PremiumCompany Announcements
CSPC Pharmaceutical’s SYS6040 Receives Clinical Trial Approval in China
PremiumCompany Announcements
CSPC Innovation Reports Significant Financial Decline in 2024
PremiumCompany Announcements
CSPC Pharmaceutical Group Schedules Board Meeting for Annual Results---
Bulls Say, Bears Say
Bulls Say
Analyst RecommendationAnalyst maintains a BUY recommendation, expecting CSPC's revenue and net profit to increase in FY25 and FY26, supported by out-licensing deals.
New Product SalesThe Company expects incremental sales from newly launched products, which should help partially offset the drag from legacy products.
Out-Licensing DealsCSPC's continued out-licensing deals could be a key driver of earnings growth, with forecasted revenue and net profit increases.
Bears Say
Margin ErosionThe significant decline in net profit is attributed to margin erosion caused by large price cuts under the '3+N' Alliance provincial VBP program.
Profit WarningCSPC released profit warning for FY24, with management expecting net profit to decline by 26% due to weak finished drug sales.
RevenueInventory destocking in oncology products continues, with a sharp fall in oncology revenue mainly due to significant price cuts.
---
Options Prices
Currently, No data available
---
Ownership Overview
―
Insiders
3.51%
Mutual Funds
― Other Institutional Investors
89.33% Public Companies and
Individual Investors
1093 FAQ
What was CSPC Pharmaceutical Group ’s price range in the past 12 months?
CSPC Pharmaceutical Group lowest stock price was HK$4.27 and its highest was HK$7.83 in the past 12 months.
What is CSPC Pharmaceutical Group ’s market cap?
CSPC Pharmaceutical Group ’s market cap is HK$63.73B.
When is CSPC Pharmaceutical Group ’s upcoming earnings report date?
CSPC Pharmaceutical Group ’s upcoming earnings report date is May 21, 2025 which is in 46 days.
How were CSPC Pharmaceutical Group ’s earnings last quarter?
CSPC Pharmaceutical Group released its earnings results on Mar 28, 2025. The company reported HK$0.053 earnings per share for the quarter, missing the consensus estimate of HK$0.06 by -HK$0.006.
Is CSPC Pharmaceutical Group overvalued?
According to Wall Street analysts CSPC Pharmaceutical Group ’s price is currently Overvalued.
Does CSPC Pharmaceutical Group pay dividends?
CSPC Pharmaceutical Group pays a Annually dividend of HK$0.1 which represents an annual dividend yield of 6.83%. See more information on CSPC Pharmaceutical Group dividends here
What is CSPC Pharmaceutical Group ’s EPS estimate?
CSPC Pharmaceutical Group ’s EPS estimate is 0.17.
How many shares outstanding does CSPC Pharmaceutical Group have?
CSPC Pharmaceutical Group has 11,543,702,000 shares outstanding.
What happened to CSPC Pharmaceutical Group ’s price movement after its last earnings report?
CSPC Pharmaceutical Group reported an EPS of HK$0.053 in its last earnings report, missing expectations of HK$0.06. Following the earnings report the stock price went up 2.846%.
Which hedge fund is a major shareholder of CSPC Pharmaceutical Group ?
Currently, no hedge funds are holding shares in HK:1093
---
CSPC Pharmaceutical Group Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
HK$5.44 (-1.59% Downside)
HK$5.44 (-1.59% Downside)
News Sentiment
Neutral
Bullish news 59%
Bearish news 100%
Bearish news 100%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-28.62%
12-Months-Change
Fundamentals
Return on Equity
13.20%
Trailing 12-Months
Asset Growth
-6.81%
Trailing 12-Months
Company Description
CSPC Pharmaceutical Group
CSPC Pharmaceutical Group Limited, an investment holding company, engages in the research and development, manufacture, and sale of pharmaceutical products in the People's Republic of China, other Asian regions, the Americas, Europe, and internationally. The company operates through Finished Drugs, Bulk Products, and Functional Food and Others segments. It provides NBP soft capsules and injections for acute ischemic stroke; Oulaining capsules and injections to treat mild to moderate memory and mental impairment; Enxi to treat adult idiopathic Parkinson's disease; Duomeisu for lymphoma, multiple myeloma, ovarian and breast cancers, and other malignant tumors; Jinyouli to prevent leucopenia and infection induced by chemotherapy; and Keaili for breast cancer. The company also offers Shuluoke, Nuomoling, Weihong, and Xinweihong for various infections; Xuanning for hypertension; Encun to prevent atherosclerotic thrombosis events; Qixiao to treat upper respiratory tract infection; Linmeixin and Shuanglexin for diabetes; Gubang and Gubangjia to treat osteoporosis in postmenopausal women; and Gaoshunsong for arthritis, osteoarthritis, ankylosing spondylitis, frozen shoulder, bursuitis, tenosynovitis, acute gout, dysmenorrhea, toothache and postoperative pain, low back pain, sprain, strain, and other soft tissue injuries. In addition, it provides Debixin for various ulcer; Qimaite for acute and chronic pains; antibiotics, vitamin C, and caffeine APIs; functional food and glucose products; and healthcare services. The company was formerly known as China Pharmaceutical Group Limited and changed its name to CSPC Pharmaceutical Group Limited in March 2013. CSPC Pharmaceutical Group Limited was incorporated in 1992 and is headquartered in Shijiazhuang, the People's Republic of China.
---
1093 Stock 12 Month Forecast
Average Price Target
HK$5.44
▼(-1.59% Downside)
Technical Analysis
Ping An Insurance Company of China
―
Sino Biopharmaceutical
―
China Medical System Holdings
―
Livzon Pharmaceutical Group
―
China Resources Pharmaceutical Group Ltd.
―
Best Analysts Covering 1093
1 Year
1 Year Success Rate
1/8 ratings generated profit
1 Year Average Return
-14.70%
reiterated a buy rating 5 days ago
Copying Jill Wu's trades and holding each position for 1 Year would result in 12.50% of your transactions generating a profit, with an average return of -14.70% per trade.
---